The DOI matches its Crossref record; 201 of the 202 references it cites were found in a registry or an index; 4 of the 31 sources its claims cite were checked for support.
Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline
Open accessAbstract
Objective The aim is to provide guidelines for the evaluation and management of adults with hypoglycemic disorders, including those with diabetes mellitus. Evidence Using the recommendations of the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system, the quality of evidence is graded very low (plus sign in circle ooo), low (plus sign in circle plus sign in circle oo), moderate (plus sign in circle plus sign in circle plus sign in circle o), or high (plus sign in circle plus sign in circle plus sign in circle plus sign in circle). Conclusions We recommend evaluation and management of hypoglycemia only in patients in whom Whipple's triad--symptoms, signs, or both consistent with hypoglycemia, a low plasma glucose concentration, and resolution of those symptoms or signs after the plasma glucose concentration is raised--is documented. In patients with hypoglycemia without diabetes mellitus, we recommend the following strategy. First, pursue clinical clues to potential hypoglycemic etiologies--drugs, critical illnesses, hormone deficiencies, nonislet cell tumors. In the absence of these causes, the differential diagnosis narrows to accidental, surreptitious, or even malicious hypoglycemia or endogenous hyperinsulinism. In patients suspected of having endogenous hyperinsulinism, measure plasma glucose, insulin, C-peptide, proinsulin, beta-hydroxybutyrate, and circulating oral hypoglycemic agents during an episode of hypoglycemia and measure insulin ant…
Overview
CoChat Summary
TL;DR
This Endocrine Society clinical practice guideline, developed using the GRADE system, provides recommendations for evaluating and managing hypoglycemic disorders in adults with and without diabetes. It emphasizes documenting Whipple's triad before initiating any workup and frames treatment-induced hypoglycemia as the limiting factor in diabetes glycemic management.
Key findings
- Hypoglycemia should be evaluated and managed only when Whipple's triad is documented (symptoms/signs consistent with hypoglycemia, a low plasma glucose, and resolution after glucose is raised) (1QQQQ).
- In seemingly well patients, endogenous hyperinsulinism is documented by glucose <55 mg/dl (3.0 mmol/liter) with insulin ≥3.0 U/ml (18 pmol/liter), C-peptide ≥0.6 ng/ml (0.2 nmol/liter), and proinsulin ≥5.0 pmol/liter; β-hydroxybutyrate ≤2.7 mmol/liter and a glucose rise ≥25 mg/dl (1.4 mmol/liter) after iv glucagon indicate insulin (or IGF) mediation.
- Insulinoma incidence is approximately 1 in 250,000 patient-years; recurrence after resection is 7% without MEN-1 and 21% with MEN-1. CT detects 70–80%, MRI about 85%, and endoscopic ultrasound in some centers >90%.
- In diabetes, defective glucose counterregulation increases severe hypoglycemia risk 25-fold or more, and hypoglycemia unawareness confers a 6-fold increased risk. In the ACCORD trial, 5.0% of intensive-therapy vs 4.0% of standard-therapy patients died (HR 1.22; 95% CI 1.01–1.46; P=0.04). The UK Hypoglycemia Study reported severe hypoglycemia prevalence of 7% and 25% and incidence of 10 and 70 episodes per 100 patient-years in T2DM patients on insulin for <2 vs >5 years.
Methods
- Guideline development by a Task Force using the GRADE system, with strong recommendations phrased "we recommend" (1) and weak recommendations "we suggest" (2); evidence quality graded QEEE (very low) to QQQQ (high).
- Recommendations cover workup of hypoglycemia, evaluation/management in persons without diabetes, and evaluation/management in persons with diabetes, each linked to Evidence, Values, and Remarks sections.
- Evidence base includes clinical observations, randomized trials (e.g., ACCORD, DCCT, UKPDS), and population-based studies; suggested protocols for a prolonged diagnostic fast (up to 72 h) and a 5-h mixed-meal test are provided.
Limitations
- Stated: because hypoglycemic disorders are rare in persons without diabetes, recommendations for their evaluation and management rely largely on clinical experience, and much lower quality evidence supports the recommended strategy compared with strategies with minor modifications or omissions.
- Stated: standards for interpreting the mixed-meal test have not been established, so fasting criteria are applied to mixed-meal results; the dose-response relationship and time course of oral carbohydrate treatment of hypoglycemia cannot be stated with confidence.
- Stated: reported hypoglycemia event rates in diabetes are generally underestimates due to difficulty of ascertainment, and compelling evidence that continuous glucose sensing reliably helps patients prevent hypoglycemia is still needed. Evident from the text: this 2008 guideline predates several therapies and technologies discussed as emerging.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
4 Valid · 0 Not valid · 8 Not checked · 13 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Treatment-induced hypoglycemia is the limiting factor in the glycemic management of diabetes (12,16,84).”
§ Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline > Background
What the sources say
- Not matchedcites [12] Cryer, 2008, Glucose homeostasis and hypoglycemia, In: Kronenberg H, Melmed S, Polonsky K, Larsen P, eds. Williams textbook of endocrinology, 11th ed. Philadelphia: Saunders, an imprint of Elsevier, Inc.;
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites [16] Cryer, 2004, Diverse causes of hypoglycemia-associated autonomic failure in diabetes., N Engl J Med source
- Supportedcites [84] Cryer, 2002, Hypoglycaemia: the limiting factor in the glycaemic management of type I and type II diabetes., Diabetologia source
The Perspective (p. 10) explicitly states that iatrogenic hypoglycaemia remains the limiting factor in the glycaemic management of diabetes. “Iatrogenic” matches the claim’s “treatment-induced.” (LLM, conf=0.95)
- Not matched
Every source the paper cites for this claim was checked and supports it.
In the paper
“The ADA Workgroup on Hypoglycemia recommended that persons with drug-treated diabetes become concerned about developing hypoglycemia at a plasma glucose concentration of 70 mg/dl (3.9 mmol/liter) or less (136).”
§ Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline > 3.1 Evidence
What the sources say
- Supportedcites [136] Diabetes Care source
The Workgroup defines both documented symptomatic and asymptomatic hypoglycemia at a measured plasma glucose concentration of 70 mg/dl (3.9 mmol/l) or less. In “Asymptomatic hypoglycemia” (page unavailable), it describes that cutoff as a conservative lower limit for people with diabetes, supporting the cited advice to be concerned at that level. (LLM, conf=0.88)
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The concept of hypoglycemia-associated autonomic failure (HAAF) in diabetes is based on pivotal findings in nondiabetic individuals (97) and patients with T1DM (101) and was first documented in T1DM (89).”
§ Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline > TABLE 4. Suggested protocol for a prolonged diagnostic fast
What the sources say
- Not checked — no full text of the sourcecites [97] Heller, 1991, Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humans., Diabetes source
- Not checked — no full text of the sourcecites [101] Davis, 1992, Further defects in counterregulatory responses induced by recurrent hypoglycemia in IDDM., Diabetes source
- Partly supportedcites [89] Dagogo-Jack, 1993, Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia., J Clin Invest sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says the study’s data document that recent antecedent hypoglycemia can induce HAAF in patients with insulin-dependent diabetes mellitus (type 1 diabetes). The paper does not establish that this was the first documentation of HAAF in that population. (LLM, conf=0.78)
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Drugs are the most common cause of hypoglycemia (12, 18 -21).”
§ Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline > General differential diagnosis
What the sources say
- Not matchedcites [12] Cryer, 2008, Glucose homeostasis and hypoglycemia, In: Kronenberg H, Melmed S, Polonsky K, Larsen P, eds. Williams textbook of endocrinology, 11th ed. Philadelphia: Saunders, an imprint of Elsevier, Inc.;
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites [18] Fischer, 1986, Hypoglycemia in hospitalized patients. Causes and outcomes., N Engl J Med source
- Not checked — no full text of the sourcecites [19] Malouf, 1985, Hypoglycemia: causes, neurological manifestations, and outcome., Ann Neurol source
- Not checked — no full text of the sourcecites [20] Marks, 1999, Drug-induced hypoglycemia., Endocrinol Metab Clin North Am source
- Partly supportedcites [21] Park-Wyllie, 2006, Outpatient gatifloxacin therapy and dysglycemia in older adults., N Engl J Med sourceExperimental — accuracy not yet measured
The Hypoglycemia results (page unavailable) associate recent gatifloxacin treatment with a higher risk of hypoglycemia in older adults. The paper does not compare drugs with other causes of hypoglycemia, so it does not establish that drugs are the most common cause. (LLM, conf=0.84)
- Not matched
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We recommend that both the conventional risk factors and those indicative of compromised defenses against hypoglycemia be considered in a patient with recurrent treatment-induced hypoglycemia (1QQQQ).”
§ Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline > 3.4
20 more claims
Create a free account to see all 25 claims and every source verdict.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recurrent PG levels in this range may result in the development of HAAF, which increases the risk of subsequent hypoglycemia and attenuates its recognition.7,36”
From Recommendations from the Pediatric Endocrine Society for evaluation and management of persistent hypoglycemia in neonates, infants, and children (2015) · cites this paper as [7]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the setting of exogenous insulin use and normal pancreatic function, endogenous insulin secretion is suppressed, as evidenced by low c-peptide and pro-insulin.”
From Non-Diabetic Hypoglycemia: Evaluation and Management in Adults (2025) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mixed meal tolerance test (MMTT) is generally considered to be a valid diagnostic tool [12, 43].”
From Spontaneous hypoglycemia: should we mind the gap? Long-term follow-up of healthy people who met Whipple’s triad criteria (2024) · cites this paper as [12]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thresholds such as <70 mg/dL are commonly used in practice, although more stringent cutoff values (e.g., <54 mg/dL) are considered for defining clinically significant episodes [6,10].”
From Defining and Characterizing Postprandial Reactive Hypoglycemia (2026) · cites this paper as [6]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“As a result, clinical practice guidelines for adult hypoglycemic disorders developed by the Endocrine Society do not support the use of the OGTT for diagnosing postprandial hypoglycemia (39).”
From Dumping syndrome after esophageal, gastric or bariatric surgery: Pathophysiology, diagnosis, and management (2017) · cites this paper as [39]
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline > Evaluation of hypoglycemia in seemingly well individuals
“plasma C-peptide levels are usually 0.6 ng/ml (0.2 mmol/liter) or greater”
§ Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline > Evaluation of hypoglycemia in seemingly well individuals
“plasma Cpeptide concentrations of at least 0.6 ng/ml (0.2 nmol/liter)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline > Evaluation of hypoglycemia in seemingly well individuals
“plasma C-peptide levels are usually 0.6 ng/ml (0.2 mmol/liter) or greater”
§ Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline > Abstract
“C-peptide of at least 0.6 ng/ml (0.2 nmol/liter)”
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Intensive insulin therapy in critically ill patients.
Van den Berghe, G., Wouters, P., Weekers, F., Verwaest, C., Bruyninckx, F., Schetz, M., Vlasselaers, D., Ferdinande, P., Lauwers, P., & Bouillon, R. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011300 · Cited by 9,977
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Intensive insulin therapy in the medical ICU
Van den Berghe, G., Wilmer, A., Hermans, G., Meersseman, W., Wouters, P. J., Milants, I., Van Wijngaerden, E., Bobbaers, H., & Bouillon, R. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052521 · Cited by 3,639
Ohkubo, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., Kojima, Y., Furuyoshi, N., & Shichiri, M. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01064-k · Cited by 3,079
Research works printed but not linked: 5
- Cryer, 2008, Glucose homeostasis and hypoglycemia, In: Kronenberg H, Melmed S, Polonsky K, Larsen P, eds. Williams textbook of endocrinology, 11th ed. Philadelphia: Saunders, an imprint of Elsevier, Inc.;, 1503
- Service, 1987, Endocrine causes of postprandial hypoglycemia, In: Andreani D, Marks V, Lefebvre PJ, eds. Serono Symposia. New York: Raven Press;, 45
- Hirata, 1970, Insulin autoimmunity in a case with spontaneous hypoglycemia., J Japan Diab Soc, 13, 312
- Gill, 2007, Exploring the ‘dead in bed syndrome’: a real life study of nocturnal hypoglycaemia, QT interval prolongation and cardiac arrhythmia, Diabet Med, 24, 13
- Ann Intern Med, 128, 165
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389
Self-citationFalconi, M., Eriksson, B., Kaltsas, G., Bartsch, D. K., Capdevila, J., Caplin, M., Kos-Kudla, B., Kwekkeboom, D., Rindi, G., Klöppel, G., et al. (2016) · Neuroendocrinology · doi:10.1159/000443171 · Cited by 1,362
Umpierrez, G. E., Hellman, R., Korytkowski, M. T., Kosiborod, M., Maynard, G. A., Montori, V. M., Seley, J. J., & Van den Berghe, G. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2098 · Cited by 1,126
“This is the standard definition in outpatients and correlates with the initial threshold for the release of counter-regulatory hormones (128, 129).”
BackgroundSelf-citationHypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus
Whitmer, R. A. (2009) · JAMA · doi:10.1001/jama.2009.460 · Cited by 1,128
Metadata
- Authors
- Cryer, P. E., Axelrod, L., Grossman, A. B., Heller, S. R., Montori, V. M., Seaquist, E. R., & Service, F. J.
- Affiliations
- Washington University in St. Louis (US)
- Harvard University (US)
- Queen Mary University of London (GB)
- University of Sheffield (GB)
- Mayo Clinic (V.M.M., F.J.S.), Rochester, Minnesota 55905
- University of Minnesota (US)
- Mayo Clinic (US)
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2009-03-01
- Volume
- 94
- Issue
- 3
- Pages
- 709-728
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2116145810
- Cited by
- 1,277
- References
- 202
- Citations by year
- 2026: 55 · 2025: 69 · 2024: 92 · 2023: 111 · 2022: 83 · 2021: 105 · 2020: 95 · 2019: 73 · 2018: 68 · 2017: 77 · 2016: 75 · 2015: 85 · 2014: 76 · 2013: 79 · 2012: 48
- FWCI
- 20.76
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- hypoglycemia, diabetes mellitus, Whipple's triad, differential diagnosis of hypoglycemia, endogenous hyperinsulinism, insulin antibodies, sulfonylurea-induced hypoglycemia, drug-induced hypoglycemia, critical illness, hormone deficiency
- MeSH terms
- Adult, Diabetes Mellitus, Humans, Hypoglycemia, Risk Factors, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-27 (prompt extract-v2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline. https://app.cochat.ai/papers/10.1210/jc.2008-1410
- The paper
- Cryer, P. E., Axelrod, L., Grossman, A. B., Heller, S. R., Montori, V. M., Seaquist, E. R., & Service, F. J. (2009). Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2008-1410
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.